Screening for novel therapeutic target molecule focused on the aberrant epigenetic gene regulation in renal cell carcinoma.
Project/Area Number |
25870348
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor biology
Urology
|
Research Institution | Kyoto University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | 腎細胞癌 / エピジェネティクス |
Outline of Final Research Achievements |
The aim of this project is that the screening and validation of the novel target molecule based on the results of gene mutation analysis in renal cell carcinoma (RCC). Using first screening we found some epigenetic related genes as useful candidate target genes. Moreover, the shRNA for these candidate genes inhibited cell growth significantly in VHL gene mutant cells in vitro second screening, and showed same results in vivo. These results suggested that these candidate target genes are anticipated as the novel target molecule in RCC and the screening methods used in this project is useful.
|
Report
(3 results)
Research Products
(4 results)
-
-
-
-
[Presentation] Development of new therapeutic strategy for VHL hereditary cancer disease by using patient-derived iPS cells.2014
Author(s)
中村英二郎, 室伏善照, 今村恵子, 丹羽明, 杉山愛子, 木下和生, 新垣隆一郎, 柴崎昇, 山崎俊成, 神波大己, 斎藤潤, 井上治久, 小川修
Organizer
第73 回日本癌学会学術集会
Place of Presentation
横浜
Year and Date
2014-09-25 – 2014-09-27
Related Report